Aster 20 mg (Tablet)

Title

• Aster 20 mg Tablet

Categories

• Medicine
• Pharmaceutical

Description

• A selective inhibitor of HMG-CoA reductase for reducing elevated total cholesterol, LDL cholesterol, apolipoprotein B (Apo-B), and triglycerides levels in various diseases.

DosageAndAdministration

• Recommended for adults and children in different dosage ranges based on the specific condition being treated.

Indications

• Indicated for familial hypercholesterolaemia, mixed dyslipidemia, hypertriglyceridaemia, dysbetalipoproteinaemia, and coronary artery disease.

Pharmacology

• Selectively inhibits HMG-CoA reductase, lowers plasma cholesterol and lipoprotein levels, and increases hepatic LDL receptors for enhanced uptake and catabolism of LDL.

Absorption

• Rapidly absorbed after oral administration with maximum plasma concentrations occurring within 1 to 2 hours.

Distribution

• Mean volume of distribution is approximately 381 liters, with 98% bound to plasma proteins.

Metabolism

• Extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products, mainly by cytochrome P450 3A4.

Excretion

• Eliminated primarily in bile following hepatic and/or extra-hepatic metabolism with a plasma elimination half-life of approximately 14 hours.

Interaction

• Potential interactions with drugs such as cyclosporine, fibric acid derivatives, niacin, digoxin, erythromycin, antacids, colestipol, and oral contraceptives.

Contraindications

• Should not be used in patients with hypersensitivity to any component, active liver disease, unexplained persistent elevations of serum transaminases, or history of serious adverse reaction to HMG-CoA reductase inhibitors.

SideEffects

• Common side effects include constipation, flatulence, dyspepsia, abdominal pain, infection, headache, back pain, rash, asthenia, arthralgia, and myalgia.

PregnancyAndLactation

• Contraindicated during pregnancy and lactation due to lack of safety data and potential for adverse effects on fetal and infant health.

PrecautionsAndWarnings

• Liver function tests should be performed before initiation of treatment, with caution in patients who consume alcohol or have a history of liver disease.

SpecialPopulations

• Impacts on geriatric, pediatric, gender, renal insufficiency, hemodialysis, and hepatic insufficiency populations.

OverdoseEffects

• Specific treatment not available, and patients should be treated symptomatically with supportive measures and monitoring of liver function and serum CK levels.

TherapeuticClass

• Belongs to the therapeutic classes of Other Anti-anginal & Anti-ischaemic drugs and Statins.

StorageConditions

• Should be kept in a dry place away from light and heat, out of the reach of children.

ChemicalStructure

• Molecular formula is C33H35FN2O5, with a chemical structure involving ortho- and parahydroxylated derivatives and various beta-oxidation products.

CommonlyAskedQuestions

• Responses to common questions related to its uses, dosages, side effects, storage, and precautions.

AbsorptionTiming

• Maximum plasma concentrations occur within 1 to 2 hours after oral administration.

Bioavailability

• The absolute bioavailability of Atorvastatin (parent drug) is approximately 14%.

VolumeOfDistribution

• Mean volume of distribution of Atorvastatin is approximately 381 liters.

ProteinBinding

• Atorvastatin is 98% bound to plasma proteins.

MetabolismByCYP3A4

• In vitro studies suggest the importance of Atorvastatin metabolism by cytochrome P450 3A4.

EliminationHalfLife

• Mean plasma elimination half-life of Atorvastatin in humans is approximately 14 hours.

EffectOnLDLReceptors

• Increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.

MyopathyRisk

• The risk of myopathy is increased with concurrent administration of certain drugs such as cyclosporine, fibric acid derivatives, and erythromycin.

AntacidInteraction

• When coadministered with antacid suspension, plasma concentrations of Atorvastatin decreased by approximately 35%.

ColestipolInteraction

• Plasma concentrations of Atorvastatin decreased by approximately 25% when coadministered with colestipol.

DigoxinInteraction

• Steady-state plasma digoxin concentrations may increase by approximately 20% when coadministered with Atorvastatin.

ErythromycinInteraction

• Plasma concentrations of Atorvastatin increased by approximately 40% with coadministration of erythromycin.

OralContraceptivesInteraction

• Coadministration of Atorvastatin and an oral contraceptive may increase AUC values for norethindrone and ethinyl estradiol.

WarfarinInteraction

• No clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.

LiverFunctionTest

• Liver function tests should be performed before the initiation of treatment and periodically thereafter.

CautiousUsageWithAlcohol

• Aster should be used with caution in patients who consume substantial quantities of alcohol.

IncreaseInCKLevels

• Aster therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.

IncreasedPlasmaConcentrationsInElderly

• Plasma concentrations of Aster are higher in healthy elderly subjects than in young adults.

NoInfluenceOnRenalDysfunction

• Renal disease has no influence on the plasma concentrations or LDL-C reduction of Aster.

HemodialysisNotExpectedToEnhanceClearance

• Hemodialysis is not expected to significantly enhance clearance of Aster since the drug is extensively bound to plasma proteins.

MarkedlyIncreasedPlasmaConcentrationsInHepaticDysfunction

• In patients with chronic alcoholic liver disease, plasma concentrations of Aster are markedly increased.

MolecularFormula

• C33H35FN2O5

DrugImage

• URL to chemical structure image of Atorvastatin Calcium.

QuickTips

• General tips for safe usage and potential adverse effects such as diarrhea, fatigue, liver problems, and blood sugar level monitoring.

MedicationDuration

• Duration of treatment should be as prescribed and should not be stopped abruptly without medical advice.

NonThinningOfBlood

• Aster 20 mg Tablet does not cause thinning of the blood.

NotRecommendedForChildrenUnder10

• Aster 20 mg Tablet should not be given to children who are less than 10 years old.

PotentialImpactOnDiabetes

• Aster 20 mg Tablet is known to increase the blood sugar levels and requires regular monitoring in diabetic patients.

SideEffectsWarrantingMedicalAttention

• Several side effects may warrant medical attention, including muscle pain, breathing difficulty, and cough.

SafeForLongTermUse

• Considered safe for long term use if taken exactly as directed by the doctor.

PossibleEffectsOnMemory

• Memory loss is a very rare side effect of Aster 20 mg Tablet and should be discussed with a doctor if experienced.

StorageAndDisposalInstructions

• Aster 20 mg Tablet should be stored at room temperature, away from heat and direct light, and kept out of the reach of children and pets.

Related Brands

• Aster 10 mg (Tablet) - euro-pharma-ltd
• Optivas 20 mg (Tablet) - concord-pharmaceuticals-ltd
• Optivas 10 mg (Tablet) - concord-pharmaceuticals-ltd
• Zuvas 20 mg (Tablet) - benham-pharmaceuticals-ltd
• TCL-R 40 mg (Tablet) - aristopharma-ltd